Oncotarget

Clinical Research Papers:

Upregulation of chemokine receptor CCR10 is essential for glioma proliferation, invasion and patient survival

Lingchao Chen, Xing Liu, Hai-Yan Zhang, Wenzong Du, Zhiyong Qin, Yu Yao, Ying Mao and Liangfu Zhou _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2014; 5:6576-6583. https://doi.org/10.18632/oncotarget.2134

Metrics: PDF 1874 views  |   HTML 2313 views  |   ?  


Abstract

Lingchao Chen1, Xing Liu2, Hai-Yan Zhang3, Wenzong Du2, Zhiyong Qin1, Yu Yao1, Ying Mao1 and Liangfu Zhou1

1 Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China

2 Department of Neurosurgery, the Second Affiliated Hospital of Harbin Medical University, Harbin, China

3 Department of Obstetrics and Gynecology, International Peace Maternal and Children’s Hospital, Shanghai Jiaotong University, Shanghai, China

Correspondence:

Liangfu Zhou, email:

Yu Yao , email:

Keywords: CCR10, Glioma, Akt pathway

Received: March 21, 2014 Accepted: June 24, 2014 Published: June 26, 2014

Abstract

Human gliomas are characterized by their invasion of normal brain structures irrespective of their grade of malignancy. Tumor cell invasion share many similarities with leukocyte trafficking, which is critically regulated by chemokines and their receptors. Here we report that the chemokine receptor CCR10 is highly expressed in human glioblastoma compared with control brain tissue. In vitro, signaling through CCL27-CCR10 mediates activation of p-Akt, and subsequently induces proliferation and invasive responses. Cell proliferation and invasion promoted by CCL27 were blocked by inhibition of p-Akt or CCR10. In vivo, down-regulation of CCR10 significantly impairs growth of glioma. Clinically, High CCR10 expression in GBM correlated with p-Akt, shorter overall survival and progression-free survival (P < 0.05). Together, these findings suggest that elevated CCR10 is a critical molecular event associated with gliomagenesis.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 2134